29 completed, 19 terminated, 15 active not recruiting, 8 withdrawn. 46 Phase 1, 38 Phase 2, 3 Phase 3, 1 Early Phase 1.
Follow copanlisib: new trials by email Literature Review of copanlisib trials Research Report on copanlisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer copanlisib, Avelumab - Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Withdrawn | VA Office of Research and Development | 2025-06-02 | 2025-06-15 | |
| A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer Copanlisib, Degarelix, Radical Prostatectomy - Prostate Cancer | Phase 1 / Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2024-01-11 | 2024-10-31 | |
| Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Copanlisib, fulvestrant - Endometrial Cancer, Ovarian Cancer | Phase 2 | Terminated | M.D. Anderson Cancer Center | 7 | 2022-09-27 | 2026-01-09 |
| A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions Copanlisib (BAY80-6946) - Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | Completed | Bayer | 6 | 2022-07-01 | 2024-10-24 | |
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-06-30 | 2023-09-26 | |
| Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Copanlisib Hydrochloride, Venetoclax - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 8 | 2022-06-29 | 2026-04-20 |
| Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas Rituximab, Etoposide, Copanlisib - Burkitt Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 8 | 2022-03-24 | 2024-07-09 |
| BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors Copanlisib, Elimusertib - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2022-03-22 | 2022-05-27 | |
| Study of Copanlisib and Ketogenic Diet Copanlisib, Ketogenic Diet - Follicular Lymphoma, Endometrial Cancer | Phase 2 | Terminated | Columbia University | 1 | 2022-02-10 | 2025-03-04 |
| Copanlisib Plus Venetoclax in R/R DLBCL Copanlisib, Venetoclax - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 48 | 2021-09-08 | 2026-01-07 |
| Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL Copanlisib - Leukemia, Acute Lymphocytic | Early Phase 1 | Terminated | Dorothy Sipkins, MD, PhD | 3 | 2021-06-21 | 2023-12-21 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer Copanlisib, Pertuzumab, Trastuzumab - Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2021-05-20 | 2025-10-01 |
| Lung Cancer With Copanlisib and Durvalumab Durvalumab, Copanlisib - Non Small Cell Lung Cancer | Phase 1 | Completed | Zhonglin Hao | 11 | 2021-05-12 | 2025-11-18 |
| Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2021-03-01 | 2026-07-31 |
| Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL Ibrutinib, Copanlisib, Acalabrutinib - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Withdrawn | Inhye Ahn | 2021-02-18 | 2025-05-22 | |
| A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden Copanlisib, Obinutuzumab - Follicular Lymphoma | Phase 2 | Unknown | Ludwig-Maximilians - University of Munich | 98 | 2020-10-19 | 2024-03-12 |
| Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma Copanlisib - Diffuse Large B-cell Lymphoma | Phase 2 | Terminated | Fondazione Italiana Linfomi - ETS | 37 | 2020-08-18 | 2025-08-08 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2020-07-17 | 2026-06-17 |
| Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers I-124 PET/CT lesion dosimetry, Vemurafenib, Copanlisib - Thyroid Carcinoma, Thyroid Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 8 | 2020-06-26 | 2025-09-08 |
| Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL Copanlisib, R-CHOP Chemotherapy - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | University Hospital Muenster | 62 | 2020-06-19 | 2026-07-30 |
Showing 20 of 73. Sign in to see all of them.
Lymphoma, Non-Hodgkin (15) · Neoplasm Metastasis (9) · Breast Neoplasms (8) · Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma, Follicular (6) · Neoplasms (6) · Lymphoma (5) · Endometrial Neoplasms (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, B-Cell, Marginal Zone (4) · Multiple Myeloma (4) · Hodgkin Disease (3) · Lymphoma, Mantle-Cell (3) · Ovarian Neoplasms (3) · Prostatic Neoplasms (3)
Bayer (21) · National Cancer Institute (NCI) (16) · Memorial Sloan Kettering Cancer Center (4) · M.D. Anderson Cancer Center (3) · Cancer Trials Ireland (2) · City of Hope Medical Center (2) · Columbia University (2) · University of Washington (2) · Brown University (1) · Chonnam National University Hospital (1) · Christian Buske (1) · Dana-Farber Cancer Institute (1) · Dorothy Sipkins, MD, PhD (1) · Fondazione Italiana Linfomi - ETS (1) · Fox Chase Cancer Center (1)
United States (50) · Germany (10) · South Korea (7) · Belgium (6) · Canada (6) · France (6) · Ireland (6) · Italy (6) · Poland (5) · Russia (5) · Singapore (5) · Spain (5) · Taiwan (5) · Australia (4) · Brazil (4)
Ryan Lynch (2) · Senthilkumar Damodaran (2) · Timothy A Yap (2) · A P Chen (1) · Alan L Ho, MD, PhD (1) · Alessandro D Santin (1) · Alexey Danilov (1) · Alexey V Danilov (1) · Anastasios Stathis, MD (1) · Benedito Carneiro, MD, MS (1) · Changchun Deng, MD, PhD (1) · Chong-Xian Pan, MD PhD (1) · Christian Buske, MD (1)
PMID 38226495, PMID 26586415, PMID 27672108, PMID 28633365, PMID 31029646, PMID 31619463, PMID 32060403, PMID 32314268, PMID 32379297, PMID 32463741, PMID 33048619, PMID 33289918, PMID 33560394, PMID 33848462, PMID 34187401, PMID 34322775, PMID 34389273, PMID 35133871, PMID 35138919, PMID 35322287, PMID 36351402, PMID 37053535, PMID 37171634, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39058951, PMID 39666929, PMID 39693587, PMID 39863139, PMID 39913886, PMID 40550489, PMID 40865033, PMID 41066729, PMID 41528970, PMID 42493490, PMID 5035790
U10CA180820 (4), UM1CA186704 (4), UM1CA186688 (3), 2014 (2), 2015 (2), 2018 (2), P30CA033572 (2), U10CA180868 (2), U24CA196172 (2), UM1CA186689 (2), 2016 (1), 2017 (1), UM1CA186686 (1), UM1CA186709 (1), ZIABC011078 (1)